{"nct_id":"NCT04938817","title":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2021-08-19","start_date_type":"ACTUAL","primary_completion_date":"2026-05-20","primary_completion_date_type":"ESTIMATED","completion_date":"2029-12-10","completion_date_type":"ESTIMATED","phases":["PHASE1","PHASE2"],"tickers":["MRK"]}